Nxera Pharma & Antiverse Collaborate to Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

Overview

Nxera Pharma (Nxera)– formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs).

About the Collab

• The collaboration combines Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries,’ with Nxera’s NxWave platform, a powerful tool for GPCR target selection, validation and structural determination. 
• The partnership aims to bring transformative therapies for multiple diseases of high unmet need. 
• The first project will be aimed at designing antibodies with agonistic function for a challenging GPCR target.

The Terms of Agreement

• Under the terms of the multi-year agreement, Antiverse will receive an upfront payment and research funding and is eligible for milestone payments. 
• Nxera will retain an exclusive worldwide license to the antibody assets, providing full rights to develop and commercialize the candidates.

About the CEO: Antiverse

Murat Tunaboylu, co-founder and CEO at Antiverse, said: “Around 220 GPCRs with known disease links are undrugged, and antibodies are an essential tool in our mission to drug them. With Nxera’s expertise and support, we are confident our platform can create antibodies for these particularly challenging targets, bringing us closer to creating life-changing therapies for patients.”

Words from the President: Nxera Pharma UK

Matt Barnes, EVP, president of Nxera Pharma UK and head of R&D, said: “Our NxWave platform has proven utility in unlocking GPCRs to antibody discovery and combining Nxera’s capabilities with Antiverse’s generative AI antibody design platform enables us to explore this exciting opportunity further, with the aim of developing new biologic therapeutics for multiple diseases, where there is high unmet patient need.”

About the Company

Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!